Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases
Eli Lilly (LLY) has entered into a landmark agreement with Superluminal Medicines, a privately held biotech firm, to harness artificial intelligence in the race to develop innovative obesity drugs. The deal, announced Thursday, is valued at up to $1.3 billion and grants Lilly access to Superluminal’s proprietary AI-driven drug discovery platform.
The collaboration aims to accelerate the identification and development of potential drug candidates targeting cardiometabolic diseases and obesity, a market projected to reach $150 billion within the next decade. Under the terms, Lilly will hold exclusive rights to develop and commercialize any drug candidates discovered through the partnership. Superluminal stands to receive upfront and milestone payments, an equity investment, and tiered royalties on net sales.
Superluminal’s leading program focuses on the melanocortin 4 receptor, a protein linked to rare genetic forms of obesity. This candidate is slated to begin human trials next year, signaling a strategic move toward both rare and more widespread obesity treatments.
Lilly has been aggressively expanding its obesity portfolio, including a 2023 partnership with Hong Kong-listed Laekna to develop an experimental therapy designed to help patients lose weight while maintaining muscle mass. This latest alliance underscores the company’s commitment to next-generation drug innovation through both in-house research and strategic collaborations.
For Superluminal, the deal represents a major validation of its AI-enabled approach, which promises to speed up the traditionally lengthy drug discovery process. By combining Lilly’s clinical and commercial expertise with advanced computational tools, the partnership aims to address one of the world’s fastest-growing health challenges with greater speed and precision.
If successful, the collaboration could yield breakthrough therapies that reshape obesity treatment and strengthen Lilly’s position as a global leader in the field.
You might like this article:Ulta and Target to End Mini-Store Partnership in 2026
